Cardiff Oncology Stock Today

CRDF Stock  USD 2.51  0.04  1.62%   

Performance

0 of 100

 
Weak
 
Strong
Very Weak

Odds Of Distress

Less than 8

 
High
 
Low
Low
Cardiff Oncology is trading at 2.51 as of the 14th of July 2024. This is a 1.62 percent increase since the beginning of the trading day. The stock's lowest day price was 2.37. Cardiff Oncology has only a 8 % chance of going through financial distress over the next few years, but has generated negative returns over the last 90 days. Equity ratings for Cardiff Oncology are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 14th of June 2024 and ending today, the 14th of July 2024. Click here to learn more.
Business Domain
Pharmaceuticals, Biotechnology & Life Sciences
IPO Date
27th of July 2004
Category
Healthcare
Classification
Health Care
Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California. Cardiff Oncology operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 44.74 M outstanding shares of which 4.22 M shares are currently shorted by private and institutional investors with about 5.65 trading days to cover. More on Cardiff Oncology

Moving together with Cardiff Stock

  0.75VRDN Viridian Therapeutics Buyout TrendPairCorr
  0.71VTYX Ventyx BiosciencesPairCorr

Moving against Cardiff Stock

  0.64PFE Pfizer Inc Aggressive PushPairCorr
  0.61VRAX Virax Biolabs GroupPairCorr
  0.48EWTX Edgewise TherapeuticsPairCorr
  0.47XWEL XWELL IncPairCorr
  0.34MRK Merck Company Financial Report 6th of August 2024 PairCorr
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores

Cardiff Stock Highlights

ESG Sustainability
Environmental
Governance
Social
Business ConcentrationBiotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors)
Average Analyst Recommendation
Financial Strength
Current ValueLast YearChange From Last Year 10 Year Trend
Asset Turnover0.00570.006
Notably Down
Slightly volatile
Total Current Liabilities5.4 M10.4 M
Way Down
Slightly volatile
Non Current Liabilities Total1.4 M1.5 M
Notably Down
Slightly volatile
Debt Levels
Cardiff Oncology can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Cardiff Oncology's financial leverage. It provides some insight into what part of Cardiff Oncology's total assets is financed by creditors.
Liquidity
Cardiff Oncology currently holds 2.15 M in liabilities with Debt to Equity (D/E) ratio of 0.02, which may suggest the company is not taking enough advantage from borrowing. Cardiff Oncology has a current ratio of 14.72, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Cardiff Oncology's use of debt, we should always consider it together with its cash and equity.

Free Cash Flow

(29.9 Million)
Cardiff Oncology (CRDF) is traded on NASDAQ Exchange in USA. It is located in 11055 Flintkote Avenue, San Diego, CA, United States, 92121 and employs 31 people. Cardiff Oncology is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 112.29 M. Cardiff Oncology conducts business under Biotechnology sector and is part of Health Care industry. The entity has 44.74 M outstanding shares of which 4.22 M shares are currently shorted by private and institutional investors with about 5.65 trading days to cover. Cardiff Oncology currently holds about 122.01 M in cash with (30.89 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.82, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Cardiff Oncology Probability Of Bankruptcy
Ownership Allocation
Cardiff Oncology holds a total of 44.74 Million outstanding shares. Cardiff Oncology shows 7.54 percent of its outstanding shares held by insiders and 21.75 percent owned by other corporate entities. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Cardiff Ownership Details

Cardiff Stock Institutional Holders

InstituionRecorded OnShares
State Street Corporation2024-03-31
139.9 K
Qube Research & Technologies2024-03-31
127.3 K
Man Group Plc2024-03-31
112.8 K
Renaissance Technologies Corp2024-03-31
86.1 K
Northern Trust Corp2024-03-31
85.5 K
Susquehanna International Group, Llp2024-03-31
83.3 K
Citigroup Inc2024-03-31
83.1 K
Morgan Stanley - Brokerage Accounts2024-03-12
79.4 K
Hrt Financial Llc2024-03-31
67.9 K
Vanguard Group Inc2024-03-31
1.9 M
Laurion Capital Management Lp2024-03-31
928.7 K
View Cardiff Oncology Diagnostics

Cardiff Oncology Historical Income Statement

At this time, Cardiff Oncology's Total Operating Expenses is most likely to increase significantly in the upcoming years. The Cardiff Oncology's current Total Other Income Expense Net is estimated to increase to about 4.2 M, while Operating Income is forecasted to increase to (43.1 M). View More Fundamentals

Cardiff Stock Against Markets

Cardiff Oncology Corporate Management

James LevineChief OfficerProfile
Mark ErlanderCEO DirectorProfile
Vicki KelemenChief OfficerProfile
Tod SmealChief OfficerProfile
Brigitte LindsaySenior FinanceProfile
MD FACPChief OfficerProfile
Charles RPhSenior AffairsProfile

Additional Information and Resources on Investing in Cardiff Stock

When determining whether Cardiff Oncology is a strong investment it is important to analyze Cardiff Oncology's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Cardiff Oncology's future performance. For an informed investment choice regarding Cardiff Stock, refer to the following important reports:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cardiff Oncology. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment.
For more detail on how to invest in Cardiff Stock please use our How to Invest in Cardiff Oncology guide.
You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cardiff Oncology. If investors know Cardiff will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cardiff Oncology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.90)
Revenue Per Share
0.014
Quarterly Revenue Growth
1.47
Return On Assets
(0.31)
Return On Equity
(0.51)
The market value of Cardiff Oncology is measured differently than its book value, which is the value of Cardiff that is recorded on the company's balance sheet. Investors also form their own opinion of Cardiff Oncology's value that differs from its market value or its book value, called intrinsic value, which is Cardiff Oncology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cardiff Oncology's market value can be influenced by many factors that don't directly affect Cardiff Oncology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cardiff Oncology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Cardiff Oncology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cardiff Oncology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.